Paeds Vivas · allergy-and-immunology
Drug allergy and delabelling in children — branching viva
Branching structured-oral viva on drug allergy and delabelling in children: the false-label problem, Gell-Coombs classification and the one-hour immediate-versus-delayed threshold, why most childhood penicillin labels are wrong (viral exanthem, amoxicillin-EBV, waning IgE), the structured history, PEN-FAST risk stratification, skin testing and drug provocation, the direct oral amoxicillin challenge delabelling pathway, the severe never-re-challenge reactions, and the antibiotic-stewardship rationale.
On this page
Study tools
Target exams
Opening question
Examiner: Take me through this child. Is her penicillin-allergy label likely to be real, and what is your frame for managing it? [3]
Candidate: The label is most likely false. Around 5–10% of children carry a penicillin-allergy label, but more than 90% cannot be confirmed when formally tested — and her history is the classic false label: a maculopapular rash on day 5 of amoxicillin during a viral illness, with no systemic features. My frame is not "what antibiotic can I use instead?" but "is this allergy even real?" I will take a structured history, risk-stratify her with a validated rule, and if she is low-risk — which she appears to be — delabel her with a supervised oral amoxicillin challenge, restoring first-line therapy. [3] [10]
Examiner: Why are most childhood labels false? [10]
Candidate: Three reasons. First, the rash attributed to the antibiotic was usually caused by the intercurrent viral illness — the amoxicillin-EBV rash is the classic, but any childhood exanthem can be misattributed to the drug. Second, many labels are based on non-allergic symptoms such as gastrointestinal upset, or on second-hand family history. Third, where a true IgE allergy once existed, it wanes — most genuinely allergic children tolerate penicillin again within about ten years. So the label outlives the biology. [10] [9]
References7ShowHide
- [1]Copaescu AM; Vogrin S; James F; et al Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial. JAMA Intern Med, 2023.PMID 37459086
- [2]Trubiano JA; Vogrin S; Chua KYL; et al Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Intern Med, 2020.PMID 32176248
- [3]Wong T; Atkinson A; t'Jong G; et al Beta-lactam allergy in the paediatric population. Paediatr Child Health, 2020.PMID 32042244
- [4]Romano A; Atanaskovic-Markovic M; Barbaud A; et al Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. Allergy, 2020.PMID 31749148
- [6]Srisuwatchari W; Phinyo P; Chiriac AM; et al The Safety of the Direct Drug Provocation Test in Beta-Lactam Hypersensitivity in Children: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract, 2023.PMID 36528293
- [9]Joerger T; Taylor MG; Li Y; et al Impact of Penicillin Allergy Labels on Children Treated for Outpatient Respiratory Infections. J Pediatric Infect Dis Soc, 2023.PMID 36461664
- [10]Stone CA Jr; Trubiano J; Coleman DT; et al The challenge of de-labeling penicillin allergy. Allergy, 2020.PMID 31049971